Ronald W. Barrett
Director/Board Member at JANUX THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Funck | M | 62 | 37 years | |
| Gordon Ringold | M | 73 |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001.
Quadriga BioSciences, Inc.
 Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | 15 years |
| David Campbell | M | 65 | 7 years | |
| Jeffrey A. Munsie | M | 47 | 5 years | |
| Andy Meyer | M | 40 | 3 years | |
| Marc A. Becker | M | 52 | 6 years | |
| Sheila Gujrathi | M | 53 | 3 years | |
| Alana McNulty | F | 61 | 3 years | |
| Winston Kung | M | 48 | 2 years | |
| Jake Simson | M | 38 | 3 years | |
| Justine E. Koenigsberg | F | - | 16 years | |
| Jay Lichter | M | 62 | 7 years | |
| Vickie Capps | F | 62 | 3 years | |
| Brenda Van Vreeswyk | F | - | 2 years | |
| Mitch K. Goldenberg | M | - | 16 years | |
| Karen Liu | M | - |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | - |
| Byron Robinson | M | 59 | 2 years | |
| Jenna Daly | F | - | - | |
| Nabil Uddin | M | - | 10 years | |
| Peter Y. Tam | M | 60 |
Quadriga BioSciences, Inc.
Quadriga BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Quadriga BioSciences, Inc. is a privately held pharmaceutical company based in an undisclosed location. The American company is focused on developing proprietary targeted cancer therapies by exploiting the biology of aggressive forms of cancer cells that over-express certain unique amino acid transporters on their cell surfaces. The company's mission is to develop safer and more effective treatments for patients with cancer. The company was founded by Bernd Jandeleit, Kerry J. Koller, and Wolf-Nicolas Fischer. Gordon Ringold has been the CEO of the company since 2015. | - |
| Virginia Braman | F | - | 4 years | |
| Thomas DiRaimondo | M | - | 6 years | |
| Charles Winter | M | - | 3 years | |
| Christine Boisclair | F | - | 8 years | |
| Tighe Reardon | M | 48 | 7 years | |
| Shelley Chu | M | 54 |
Medikine, Inc.
 Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | - |
| Roland Buelow | M | - |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | 2 years |
| James Cassella | M | 69 | 9 years | |
| James Pennington | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Vincent Angotti | M | 56 | 8 years | |
| Wendell Wierenga | M | 76 | 16 years | |
| William Rieflin | M | 64 | 12 years | |
| Mark A. Gallop | M | 61 |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | 9 years |
| James E. Shipley | M | - | 2 years | |
| Gianna M. Bosko | F | 54 | 10 years | |
| Emily Lee Kelley | F | 66 |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | 6 years |
| Stefan Heller | M | 58 | 4 years | |
| Peter Thompson | M | 64 | 2 years | |
| William J. Dower | M | - | - | |
| Lijun Wu | M | 50 | 7 years | |
| David Savello | M | 78 | - | |
| Helmut Schühsler | M | 65 | 5 years | |
| Catherine Friedman | F | 63 | 9 years | |
| Ryan Lynch | M | - | 2 years | |
| Jesper Høiland | M | 63 | - | |
| Gregory T. Bates | M | 65 | - | |
| Pauline McGowan | F | - | 9 years | |
| Lynette Herscha | F | 52 | 5 years | |
| Paul Berns | M | 57 | 11 years | |
| Mary Szela | F | 60 | 25 years | |
| Robert W. Overell | M | 69 | 6 years | |
| Thomas G. Auchincloss | M | 62 | - | |
| H. Fuller | M | 85 | - | |
| Jeryl Hilleman | F | 66 | 14 years | |
| Per G. H. Lofberg | M | 76 | 2 years | |
| Kenneth J. Nussbacher | M | 70 | 10 years | |
| Meghan Fitzgerald | M | 53 | 2 years | |
| Christine van Heek | F | 67 | - | |
| Ernest Mario | M | 85 | 3 years | |
| John Freund | M | 70 | 2 years | |
| Dennis Fenton | M | 72 | 7 years | |
| Louise Dube | M | - | 14 years | |
| David J. Wustrow | M | 65 | 4 years | |
| Terry Opgenorth | M | 68 | 20 years | |
| Corlis D. Murray | F | - | 31 years | |
| William Chase | M | 57 | 23 years | |
| Michael J. Warmuth | M | 61 | 31 years | |
| Ruben Valdez | M | - | - | |
| Carlos Alban | M | 61 | 26 years | |
| Christopher Kuebler | M | 70 | 8 years | |
| Michael Zbinovec | M | - | 8 years | |
| Brian L. Durkin | M | 63 | 30 years | |
| Keith Maynard Lingenfelter | M | - | 12 years | |
| John R. Tushar | M | 62 | - | |
| David Laskow-Pooley | M | 69 | 6 years | |
| Joe R. Sanders | M | - | 10 years | |
| Peter Virsik | M | - | 10 years | |
| Michael Carter | M | - | - | |
| Daniel M. Canafax | M | 71 | 5 years | |
| Edward Fiorentino | M | 65 | - | |
| Gail A. Sloan | F | 61 |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | 3 years |
| Philippe G. Prokocimer | M | 74 | 7 years | |
| Ryan Daws | M | 50 | 3 years | |
| Terri Sebree | F | 66 | 8 years | |
| Robert Hooper | M | 77 | 4 years | |
| Stephen P. A. Fodor | M | 70 |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | 4 years |
| Paul D. Rubin | M | 70 | 6 years | |
| Fang-Tyan Chen | M | 74 | 22 years | |
| Holger Liepmann | M | 72 | 25 years | |
| Christopher Begley | M | 71 | 18 years | |
| Peter S. DiStefano | M | 66 | 5 years | |
| Robert A. Reed | M | 63 | 3 years | |
| Douglas Liu | M | 62 | 10 years | |
| Brian Thomas Hett | M | - | 2 years | |
| Michael Williams | M | - | 11 years | |
| Gary Stevenson | M | - | 7 years | |
| Michael C. Needels | M | - |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | - |
| Thomas Woiwode | M | 52 | 2 years | |
| Dan Kisner | M | 77 | 3 years | |
| Mark C. Roessel | M | - | 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Ronald W. Barrett
- Personal Network
